NCT07148466

Brief Summary

This study aims to fill this gap by investigating the effects of scapular and upper limb proprioceptive neuromuscular facilitation techniques on shoulder pain, upper limb function \& gait in stroke with scapular dyskinesia. This study is a randomized control trial that includes 44 patients which were randomly divided into two groups each containing 22 participants. Experimental group will receive scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment and Control group will receive only Conventional treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 19, 2025

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

August 24, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 29, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 21, 2026

Completed
Last Updated

August 29, 2025

Status Verified

August 1, 2025

Enrollment Period

5 months

First QC Date

August 24, 2025

Last Update Submit

August 24, 2025

Conditions

Keywords

scapular PNF coupled with upper limb PNF

Outcome Measures

Primary Outcomes (4)

  • Fugl-Meyer Assessment of Upper Extremity (FMA-UE)

    After a stroke, the FMA-UE is frequently used to evaluate and track recovery in hemiplegic patients.. It is a specific tool for quantifying upper limb impairment and rehabilitation outcomes in stroke patients with hemiparesis. Using a 3-point ordinal scale, the assessment rates the patient's ability to complete each task: 0 denotes incapacity to execute, 1 denotes partial completion, and 2 denotes full performance. All item scores, which range from 0 to 126, are added up to determine the final score.

    6 weeks

  • Dynamic gait index (DGI)

    A participant's ability to maintain walking balance while adjusting to different task demands and dynamic situations is evaluated by the Dynamic Gait Index (DGI). It is especially helpful for people who have balance and vestibular problems, as well as those who are at risk of falling. Every item has a rating between 0 and 3, where 0 denotes significant impairment and 3 denotes normal performance. 24 is the maximum possible score. A total score of less than 19 out of 24 indicates that older adults are more likely to fall, whereas a score of more than 22 indicates safe walking.

    6 weeks

  • Visual Analogue Scale

    Hayes and Patterson employed the visual analog scale (VAS), a pain rating tool, for the first time in 1921. A single handwritten mark is placed at one point along a 10-cm line that represents a continuum between the two ends of the scale, with "no pain" at the left end (0 cm) and the "worst pain" at the right end (10 cm). Self-identified evaluations of symptoms are used to calculate scores. The patient's discomfort is calculated by measuring the distance in centimeters between the patient's marks and the scale's beginning point (left end). The figures can be used to gauge a patient's pain progression or to compare pain across people with comparable diseases. 0 No pain, 1-3 slight pain, 4-6 moderate pain, and 7-10 excruciating pain.

    6 weeks

  • 10-Meter Walk Test (10MWT)

    The test calculates walking speed over a brief distance in meters per second. To the closest tenth of a second, the total time spent walking six meters (m) is recorded. Then, 6 meters is divided by the whole time (in seconds) to convert this distance to m/s. The following categories apply to walking speeds: Family Ambulatory \<0.40 m/s; Community Ambulator ≥0.80 m/s; Limited Community Ambulator 0.40 to \<0.80 m/s

    6 weeks

Study Arms (2)

GROUP 1

EXPERIMENTAL

scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment.

Other: Scapular PNF

GROUP 2

ACTIVE COMPARATOR

Conventional treatment

Other: Conventional treatment

Interventions

scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment . It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.

GROUP 1

Conventional treatment. It includes closed kinematic chain exercises of upper limb, upper and lower extremity range of motion exercises, stretching and strengthening exercises for upper limb, trunk and lower limb, balance \& coordination, manual dexterity exercises (e.g., grasp release), and teaching of ADLs.. It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.

GROUP 2

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Sub-acute
  • MCA
  • Age bracket 40-65 years.
  • Gender Male or Female.
  • Gait baseline score (DGI less than 19)
  • Patients with spasticity between grades (+1 and 1) on the Modified Ashworth Scale (MAS).

You may not qualify if:

  • Inability to communicate/understand instructions.
  • Stroke with other neurological conditions.
  • Patient with any other psychological and medical condition.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

HBS Hospital islamabad

Islamabad, Punjab Province, 44000, Pakistan

RECRUITING

National institute of rehablitation medicine islamabad

Islamabad, Punjab Province, 44000, Pakistan

RECRUITING

Study Officials

  • Mahat zafar, MSNMPT

    Riphah International University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mahat zafar, MSNMPT

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2025

First Posted

August 29, 2025

Study Start

August 19, 2025

Primary Completion

January 20, 2026

Study Completion

February 21, 2026

Last Updated

August 29, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations